These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20090403)

  • 1. Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration.
    Schäfer-Korting M; Höltje M; Korting HC; Höltje HD
    Skin Pharmacol Physiol; 2010; 23(1):6-14. PubMed ID: 20090403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human polymerase alpha inhibitors for skin tumors. Part 2. Modeling, synthesis and influence on normal and transformed keratinocytes of new thymidine and purine derivatives.
    Höltje M; Richartz A; Zdrazil B; Schwanke A; Dugovic B; Murruzzu C; Reissig HU; Korting HC; Kleuser B; Höltje HD; Schäfer-Korting M
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):250-65. PubMed ID: 20222764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of guanosine-analog phosphonates identified by molecular modelling.
    Schwanke A; Murruzzu C; Zdrazil B; Zuhse R; Natek M; Höltje M; Korting HC; Reissig HU; Höltje HD; Schäfer-Korting M
    Int J Pharm; 2010 Sep; 397(1-2):9-18. PubMed ID: 20600723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for actinic keratosis.
    Ulrich M; Drecoll U; Stockfleth E
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):545-55. PubMed ID: 20670178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses.
    Paolino D; Celia C; Trapasso E; Cilurzo F; Fresta M
    Eur J Pharm Biopharm; 2012 May; 81(1):102-12. PubMed ID: 22414731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses.
    Resnick L; Rabinovitz H; Binninger D; Marchetti M; Weissbach H
    J Drugs Dermatol; 2009 Jan; 8(1):29-32. PubMed ID: 19180893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carriers in the topical treatment of skin disease.
    Korting HC; Schäfer-Korting M
    Handb Exp Pharmacol; 2010; (197):435-68. PubMed ID: 20217539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical therapies for skin cancer and actinic keratosis.
    Haque T; Rahman KM; Thurston DE; Hadgraft J; Lane ME
    Eur J Pharm Sci; 2015 Sep; 77():279-89. PubMed ID: 26091570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity.
    Akita Y; Kozaki K; Nakagawa A; Saito T; Ito S; Tamada Y; Fujiwara S; Nishikawa N; Uchida K; Yoshikawa K; Noguchi T; Miyaishi O; Shimozato K; Saga S; Matsumoto Y
    Br J Dermatol; 2004 Aug; 151(2):472-80. PubMed ID: 15327557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.
    Moore AY
    J Dermatolog Treat; 2009; 20(6):328-35. PubMed ID: 19954388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma.
    Tampucci S; Carpi S; Digiacomo M; Polini B; Fogli S; Burgalassi S; Macchia M; Nieri P; Manera C; Monti D
    Molecules; 2019 May; 24(9):. PubMed ID: 31075867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actinic keratosis is squamous cell carcinoma.
    Lober BA; Lober CW
    South Med J; 2000 Jul; 93(7):650-5. PubMed ID: 10923948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical application of valrubicin has a beneficial effect on developing skin tumors.
    Andersen SM; Rosada C; Dagnaes-Hansen F; Laugesen IG; de Darkó E; Dam TN; Stenderup K
    Carcinogenesis; 2010 Aug; 31(8):1483-90. PubMed ID: 20554745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of field change in actinic keratosis.
    Vatve M; Ortonne JP; Birch-Machin MA; Gupta G
    Br J Dermatol; 2007 Dec; 157 Suppl 2():21-4. PubMed ID: 18067627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours.
    Hida Y; Kubo Y; Arase S
    Br J Dermatol; 2009 Jun; 160(6):1258-63. PubMed ID: 19298285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actinic keratosis: do the numbers add up?
    Stanger CB
    Nurse Pract; 2009 Feb; 34(2):36-9. PubMed ID: 19155885
    [No Abstract]   [Full Text] [Related]  

  • 18. Photodynamic therapy for non-melanoma skin cancer.
    Szeimies RM; Morton CA; Sidoroff A; Braathen LR
    Acta Derm Venereol; 2005; 85(6):483-90. PubMed ID: 16396794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of skin cancer and pre-cancer using topical ALA-PDT--a single hospital experience.
    Wang XL; Wang HW; Guo MX; Xu SZ
    Photodiagnosis Photodyn Ther; 2008 Jun; 5(2):127-33. PubMed ID: 19356643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin.
    Hodges A; Smoller BR
    Mod Pathol; 2002 Nov; 15(11):1121-5. PubMed ID: 12429789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.